Therapeutic options in peripheral T cell lymphoma
Abstract Peripheral T cell lymphoma (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas with a very poor prognosis. The standard first-line treatments have resulted in unsatisfactory patient outcomes. With the exception of low-risk anaplastic lymphoma kinase (ALK)-positive anaplastic l...
Main Authors: | Yaping Zhang, Wei Xu, Hong Liu, Jianyong Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2016-04-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13045-016-0267-0 |
Similar Items
-
Peripheral T cell lymphoma: Not otherwise specified
by: Anusha H Pai, et al.
Published: (2015-01-01) -
Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma
by: Caiqin Xie, et al.
Published: (2020-11-01) -
Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas
by: Zachary Braunstein, et al.
Published: (2022-06-01) -
Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions
by: Maliha Khan, et al.
Published: (2021-11-01) -
Novel target and treatment agents for natural killer/T-cell lymphoma
by: Xiao-Peng Tian, et al.
Published: (2023-07-01)